159 related articles for article (PubMed ID: 37314500)
1. Pharmacology and pharmacokinetics of elacestrant.
Beumer JH; Foldi J
Cancer Chemother Pharmacol; 2023 Aug; 92(2):157-163. PubMed ID: 37314500
[TBL] [Abstract][Full Text] [Related]
2. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative,
Shah M; Lingam H; Gao X; Gittleman H; Fiero MH; Krol D; Biel N; Ricks TK; Fu W; Hamed S; Li F; Sun JJ; Fan J; Schuck R; Grimstein M; Tang L; Kalavar S; Abukhdeir A; Pathak A; Ghosh S; Bulatao I; Tilley A; Pierce WF; Mixter BD; Tang S; Pazdur R; Kluetz P; Amiri-Kordestani L
J Clin Oncol; 2024 Apr; 42(10):1193-1201. PubMed ID: 38381994
[TBL] [Abstract][Full Text] [Related]
3. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD; Bardia A; Chirn B; Reeves BA; LiCausi JA; Burr R; Wittner BS; Rai S; Patel H; Bihani T; Arlt H; Bidard FC; Kaklamani VG; Aftimos P; Cortés J; Scartoni S; Fiascarelli A; Binaschi M; Habboubi N; Iafrate AJ; Toner M; Haber DA; Maheswaran S
Breast Cancer Res Treat; 2023 Aug; 201(1):43-56. PubMed ID: 37318638
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Bardia A; Kaklamani V; Wilks S; Weise A; Richards D; Harb W; Osborne C; Wesolowski R; Karuturi M; Conkling P; Bagley RG; Wang Y; Conlan MG; Kabos P
J Clin Oncol; 2021 Apr; 39(12):1360-1370. PubMed ID: 33513026
[TBL] [Abstract][Full Text] [Related]
5. EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.
Bardia A; Aftimos P; Bihani T; Anderson-Villaluz AT; Jung J; Conlan MG; Kaklamani VG
Future Oncol; 2019 Oct; 15(28):3209-3218. PubMed ID: 31426673
[TBL] [Abstract][Full Text] [Related]
6. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC; Kaklamani VG; Neven P; Streich G; Montero AJ; Forget F; Mouret-Reynier MA; Sohn JH; Taylor D; Harnden KK; Khong H; Kocsis J; Dalenc F; Dillon PM; Babu S; Waters S; Deleu I; García Sáenz JA; Bria E; Cazzaniga M; Lu J; Aftimos P; Cortés J; Liu S; Tonini G; Laurent D; Habboubi N; Conlan MG; Bardia A
J Clin Oncol; 2022 Oct; 40(28):3246-3256. PubMed ID: 35584336
[TBL] [Abstract][Full Text] [Related]
7. Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.
Varella L; Cristofanilli M
Onco Targets Ther; 2023; 16():189-196. PubMed ID: 36993871
[TBL] [Abstract][Full Text] [Related]
8. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
9. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
[No Abstract] [Full Text] [Related]
10. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
11. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
[TBL] [Abstract][Full Text] [Related]
12. Elacestrant: a new FDA-approved SERD for the treatment of breast cancer.
Bhatia N; Thareja S
Med Oncol; 2023 May; 40(6):180. PubMed ID: 37191763
[TBL] [Abstract][Full Text] [Related]
13. Elacestrant: First Approval.
Hoy SM
Drugs; 2023 Apr; 83(6):555-561. PubMed ID: 37060385
[TBL] [Abstract][Full Text] [Related]
14. Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
Pancholi S; Simigdala N; Ribas R; Schuster E; Leal MF; Nikitorowicz-Buniak J; Rega C; Bihani T; Patel H; Johnston SR; Dowsett M; Martin LA
NPJ Breast Cancer; 2022 Nov; 8(1):125. PubMed ID: 36446866
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer.
Guglielmi G; Del Re M; Gol LS; Bengala C; Danesi R; Fogli S
Eur J Pharmacol; 2024 Apr; 969():176424. PubMed ID: 38402929
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.
Wardell SE; Nelson ER; Chao CA; Alley HM; McDonnell DP
Endocr Relat Cancer; 2015 Oct; 22(5):713-24. PubMed ID: 26162914
[TBL] [Abstract][Full Text] [Related]
17. Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer.
Hageman E; Lussier ME
Ann Pharmacother; 2023 Oct; ():10600280231206131. PubMed ID: 37888769
[TBL] [Abstract][Full Text] [Related]
18. First Approval of Elacestrant as a Selective Estrogen Receptor Degrader for the Treatment of Metastatic Breast Cancer.
De SK
Curr Med Chem; 2023 May; ():. PubMed ID: 37143269
[TBL] [Abstract][Full Text] [Related]
19. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
Wang Y; Tang SC
Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
[TBL] [Abstract][Full Text] [Related]
20. Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective.
Rugo HS
Clin Adv Hematol Oncol; 2023 Dec; 21(12):623-632. PubMed ID: 38039056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
